Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Sweden United Kingdom

US PASTEUR Act Promises More Than Other National AMR Initiatives

  • News

Executive Summary

PASTEUR Act in the US is the most promising initiative out there to address antimicrobial resistance.

You may also be interested in...



EMA Aligns Antibiotics Guideline To Help Facilitate Global Trials

The EU regulator says it supports a globally aligned approach to the development of new antimicrobial medicines.

French Consortium Pioneers New AMR Development Model

A new consortium that has won funding from the French government will focus on developing new treatments, diagnostics and surveillance and make sure that these approaches are properly valued by involving health economists in new drug development.

Support For Small Companies In AMR Space Is Crucial Now

G7 countries should look to US PASTEUR Act For Inspiration On Pull Incentives for Antimicrobials

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
Europe Sweden United Kingdom
Latest Headlines

Pink Sheet Podcast: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

See All
UsernamePublicRestriction

Register

PS145368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By